Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Response Genetics To Present New Data On Lung Cancer Supporting The Use Of Gene Expression To Help Personalize Cancer Therapy Selection
Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, will announce the results of separate analyses of KRAS gene mutations and TS and RRM1 gene expression in non-small cell lung cancer (NSCLC) during the 13th World Conference on Lung Cancer, which will be held July 31 to August 4. Results will provide insights into which patient subtypes are most likely to benefit from the commonly prescribed chemotherapies pemetrexed and gemcitabine.
generic viagra online
Senate Appropriations Subcommittee Approves Fiscal Bill Without Abstinence-Only Funding
The fiscal year 2010 Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee spending bill approved on Tuesday by voice vote does not include funding for abstinence-only programs, CQ Today reports.Subcommittee Chair Tom Harkin (D-Iowa) said that when the full committee marks up the bill on Thursday, it will not include funding for abstinence-only sex education. The bill will provide money for comprehensive sex education programs, which can include teaching abstinence. The recently approved House version (HR 3293) takes a similar approach. CQ Today calls Harkin"s support for defunding abstinence-only "another nail in the coffin" for the programs, which had grown during President George W. Bush"s administration. According to CQ Today, since taking control of Congress in 2007, Democrats have been "slowly bleeding the program," saying most research has shown that abstinence-only programs are "ineffective at ensuring teen chastity."The subcommittee approved the bill"s funding table, which would provide $163.1 billion in discretionary funding. The amount of discretionary funding is $1.6 billion more than President Obama requested, $2.1 billion more than the House bill and $3.2 billion more than the fiscal year 2009 spending bill (Wolfe, CQ Today, 7/28).
News of the day
New Study Shows Coaching To Patient Activation Levels Improves Disease Management Outcomes
People with chronic health conditions who receive coaching tailored to their level of health activation showed significant improvements in clinical outcomes, and experienced fewer hospitalizations and visits to the emergency room than those coached using traditional methods, according to a study published in the June issue of The American Journal of Managed Care.
Oncology

Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency

Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus" proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults. "Moving this pediatric trial forward is an important step in re-establishing the value of the ALTU-238 program and Altus," stated Dr. Georges Gemayel, President and Chief Executive Officer of Altus Pharmaceuticals. "This Phase 2 pediatric trial is the fifth clinical study to evaluate ALTU-238. Previous ALTU-238 studies have demonstrated pharmacokinetic and pharmacodynamic (PK/PD) profiles that are supportive of and consistent with a once-per-week dosing regimen." The Company is also announcing that Kenneth Attie, M.D., Vice President of Clinical Development and Medical Affairs at Altus Pharmaceuticals, will be presenting results from a key Phase 1 study in the ALTU-238 development program at The Endocrine Society"s 91st Annual Meeting in Washington, D.C. at the Washington Convention Center on Wednesday, June 10, 2009. The Endocrine Society"s Annual Meeting (ENDO) is a leading forum for physicians and other clinicians who treat endocrine conditions, including growth hormone disorders. Dr. Ken Attie stated, "As we present this Phase 1 data and start the Phase 2 trial, we believe ALTU-238 has the opportunity to demonstrate its unique advantages compared to daily growth hormone products as well as the other long-acting growth hormone candidates that are in development." Dr. Attie will be presenting a poster entitled, "Pharmacokinetic, Pharmacodynamic and Safety Results of ALTU-238, a Long-Acting, Crystalline Recombinant Human Growth Hormone, in Healthy Adults." The ALTU-238 Phase 1 trial evaluated the safety and PK/PD profile of a single dose of weekly ALTU-238 compared to seven injections of daily growth hormone. ALTU-238 was well tolerated in the one-week study that included 36 healthy, adult subjects. In addition, the Phase 1 PK/PD data is consistent with prior ALTU-238 clinical studies that supported a once-per-week dosing regimen. The Phase 1 trial results also indicate that the ALTU-238 material, produced at the current increased manufacturing scale, performs similarly to the material used in previous ALTU-238 studies. Altus Pharmaceuticals Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009